These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 23496666)

  • 61. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.
    Rice SJ; Miller B; Wagman M; Jamorabo DS; Liu X; Belani CP
    Curr Mol Pharmacol; 2016; 9(3):183-195. PubMed ID: 26177648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.
    Kelly RJ; Gulley JL; Giaccone G
    Clin Lung Cancer; 2010 Jul; 11(4):228-37. PubMed ID: 20630824
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
    Decoster L; Wauters I; Vansteenkiste JF
    Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment.
    Dubinett S; Sharma S
    Immunotherapy; 2009 Sep; 1(5):721-5. PubMed ID: 20636013
    [No Abstract]   [Full Text] [Related]  

  • 65. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
    Delcayre A; Shu H; Le Pecq JB
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer.
    Um SJ; Choi YJ; Shin HJ; Son CH; Park YS; Roh MS; Kim YS; Kim YD; Lee SK; Jung MH; Lee MK; Son C; Choi PJ; Chung J; Kang CD; Lee EY
    Lung Cancer; 2010 Nov; 70(2):188-94. PubMed ID: 20223553
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multimodality approach to management of stage III non-small cell lung cancer.
    Scarpaci A; Mitra P; Jarrar D; Masters GA
    Surg Oncol Clin N Am; 2013 Apr; 22(2):319-28. PubMed ID: 23453337
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [About the impact of the dendritic cell autovaccine on the results of treatment of non-small-cell lung cancer patients].
    Sovenko VM; Khranovskaia NN; Ganul AV; Ganul VL; Grinevich IuA; Orel VÉ; Skachkova OV; Svergun NN; Bororov LV; Borisiuk BO; Kobzev OI; Shevchenko AI; Semivolos AV; Kondratskiĭ IuN
    Lik Sprava; 2013 Sep; (6):68-72. PubMed ID: 25510092
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Modelling associations between time-to-event responses in pilot cancer clinical trials using a Plackett-Dale model.
    Tibaldi F; Barbosa FT; Molenberghs G
    Stat Med; 2004 Jul; 23(14):2173-86. PubMed ID: 15236423
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunotherapy of lung cancer: an update.
    Rüttinger D; Winter H; van den Engel NK; Hatz RA; Schlemmer M; Pohla H; Grützner S; Schendel DJ; Fox BA; Jauch KW
    Onkologie; 2006 Feb; 29(1-2):33-8. PubMed ID: 16514254
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TIME for a successful cancer vaccine in NSCLC?
    Butts CA; Sangha R
    Lancet Oncol; 2016 Feb; 17(2):131-132. PubMed ID: 26727164
    [No Abstract]   [Full Text] [Related]  

  • 73. [New developments in treatment of non-small cell lung cancer].
    Reinmuth N; Gröschel A; Reck M
    Pneumologie; 2013 Nov; 67(11):634-8. PubMed ID: 24198238
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunotherapy for lung cancer.
    Bradbury PA; Shepherd FA
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S164-70. PubMed ID: 18520304
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunotherapy for lung cancer.
    Hirschowitz EA; Yannelli JR
    Proc Am Thorac Soc; 2009 Apr; 6(2):224-32. PubMed ID: 19349492
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.
    Fotin-Mleczek M; Zanzinger K; Heidenreich R; Lorenz C; Thess A; Duchardt KM; Kallen KJ
    J Gene Med; 2012 Jun; 14(6):428-39. PubMed ID: 22262664
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Present and future of lung cancer vaccines.
    Raez LE; Rosenblatt JD; Podack ER
    Expert Opin Emerg Drugs; 2006 Sep; 11(3):445-59. PubMed ID: 16939384
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Advances in immunotherapy for non-small cell lung cancer.
    Reckamp KL
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):847-53. PubMed ID: 27058851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.